
PTC Therapeutics (PTCT) Stock Forecast & Price Target
PTC Therapeutics (PTCT) Analyst Ratings
Bulls say
PTC Therapeutics is a success story in the biopharmaceutical industry, with its launch of Sephience and votoplam leading to high compliance and positive patient feedback. With a potential stock value of $74 to $174 in the U.S. and EU5 market and a promising new treatment for Huntington's disease in development, PTC has potential for future growth. However, the company also faces challenges in international markets, making it important for PTC to continue to perform above current estimates.
Bears say
PTC Therapeutics is currently facing challenges that may hinder its future growth. The company's lead product, Translarna, has faced setbacks in its clinical trials and may not receive regulatory approval. In addition, the company's pipeline is heavily focused on rare diseases, which may limit its market potential. These factors, along with the high valuation of the stock, lead to a negative outlook on PTC Therapeutics's stock.
This aggregate rating is based on analysts' research of PTC Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PTC Therapeutics (PTCT) Analyst Forecast & Price Prediction
Start investing in PTC Therapeutics (PTCT)
Order type
Buy in
Order amount
Est. shares
0 shares